Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | CKS1B | P61024 | 2/20 | 0.52 |
| ▸ | SKP1 | P63208 | 2/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.52 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31185603 | 0.86 | HTR5A (0.55) | BACE1ACHECKS1BSKP1SKP2 | |
| SCHEMBL5373948 | 0.86 | BACE1 (0.49) | BACE1ACHECYP11B2CHRM2CHRM4 | |
| SCHEMBL5372246 | 0.86 | HTR5A (0.55) | BACE1ACHECKS1BSKP1SKP2 | |
| SCHEMBL5375656 | 0.85 | SMARCA2 (0.54) | BACE1ACHECHRM2CHRM4CHRM1 | |
| SCHEMBL6308917 | 0.85 | BACE1 (0.51) | BACE1ACHECYP11B2CKS1BSKP1 | |
| SCHEMBL5375431 | 0.85 | BACE1 (0.51) | BACE1ACHECKS1BSKP1SKP2 | |
| SCHEMBL5363596 | 0.85 | GBA1 (0.53) | BACE1ACHECYP11B2CKS1BSKP1 | |
| SCHEMBL2416196 | 0.85 | CYP11B2 (0.56) | BACE1ACHECYP11B2CHRM1CKS1B | |
| SCHEMBL5373904 | 0.85 | BACE1 (0.51) | BACE1ACHECKS1BSKP1SKP2 | |
| SCHEMBL5368930 | 0.85 | BACE1 (0.48) | BACE1ACHECYP11B2CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| CN-112341396-B | Novel monoacylglycerol esterase inhibitor and preparation method and application thereof | 四川大学华西医院 | 2022-07-26 | — | — | CN | disclosed |
| CN-112341396-A | Novel monoacylglycerol esterase inhibitor and preparation method and application thereof | 四川大学华西医院 | 2021-02-09 | — | — | CN | disclosed |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | SRX CARDIO, LLC | 2021-02-04 | — | — | US | disclosed |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2019-04-25 | — | — | US | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | BACE1 28/4885ACHE 1412/4885CYP11B2 2362/4885 |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | PCSK9, PCSK6, PCSK7 | BACE1 25/4885ACHE 1622/4885CYP11B2 2132/4885 |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | BACE1 33/4885ACHE 1347/4885CYP11B2 2573/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | BACE1 2275/4885ACHE 3566/4885CYP11B2 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.